Company news

Cartesian Therapeutics, Inc. news in 2024

Cartesian Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

December 2, 2024

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

November 20, 2024

Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 6, 2024

Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting

November 4, 2024

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

October 14, 2024

Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis

September 8, 2024

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

September 2, 2024

Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

August 7, 2024

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

July 1, 2024

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

July 1, 2024

Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

July 1, 2024

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

July 1, 2024

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

May 21, 2024

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

March 27, 2024

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

March 6, 2024

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland

March 4, 2024

Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity

January 7, 2024

Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

January 7, 2024

Decks in 2024